Suppression of perfluoroisobutylene induced acute lung injury by pretreatment with pyrrolidine dithiocarbamate

Journal of Occupational Health

Volumn 49, Issue 2, 2007, Pages 95-103

  Zhao, Jian ^a   Shao, Zhihua ^b   Zhang, Xigang ^c   Ding, Rigao ^a   Xu, Jin ^b   Ruan, Jinxiu ^a   Zhang, Xiancheng ^a   Wang, Hemei ^a   Sun, Xiaohong ^a   Huang, Chunqian ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b Juhua Group Cooperation   (China)

^c Beijing 307 Hospital   (China)

Author keywords

Acute lung injury; NF B activation; Perfluoroisobutylene; Pyrrolidine dithiocarbamate

Indexed keywords

ANTIOXIDANT; FLUOROCARBON; PERFLUOROISOBUTYLENE; PYRROLIDINE DERIVATIVE; PYRROLIDINE DITHIOCARBAMIC ACID; THIOCARBAMIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASE; LUNG LAVAGE; MALE; MOUSE;

ADMINISTRATION, INHALATION; ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; BRONCHOALVEOLAR LAVAGE FLUID; FLUOROCARBONS; LUNG DISEASES; MALE; MICE; PYRROLIDINES; THIOCARBAMATES;

MUS;

EID: 34247325135     PISSN: 13419145     EISSN: 13489585     Source Type: Journal    
DOI: 10.1539/joh.49.95     Document Type: Article

References (22)

1. Oberdorster G, Ferin J, Gelein J, Finkelstein R and Baggs R: Effects of PTFE fumes in the respiratory tract: a particle effect? Aerospace Medical Assiciation 65th Annual Scientific Meeting 538, A52 (1994)
2. John B: The development of penetrant protective carbon (PPC). ASA Newsletter 53, 2 (1996)
3. Brainard JR, Kinkead SA, Kober EM, Stavert DM and Lehnert BE: Potential involvement of HF in perfluoroisobutylene-induced lung injury. Toxicologist 12, 843-851 (1992)
4. Lehnert BE, Archuleta D, Behr MJ and Stavert DW: Lung injury after acute inhalation of perfluoroisobutylene: exposure concentration-response relationships. Inhal Toxicol 5, 1-32 (1993)
5. Wang HM, Ding RG, Ruan JX, Yuan BL, Sun XH, Zhan XC, Yu SZ and Qu WS: Perfluoroisobutylene-induced acute lung injury and mortality are heralded by neutrophil sequestration and accumulation. J Occup Health 43, 331-338 (2001)
6. Zhang TH, Zhang XG, Shao ZH, Ding RG, Yang SJ, Ruan JX, Sun XH, Xu J, Huang CQ, Hu ZL and Zhang XC: The prophylactic and therapeutic effects of cholinolytics on perfluoroisobutylene inhalation induced acute lung injury. J Occup Health 47, 277-285 (2005)
7. Abraham E: NF-κB activation. Crit Care Med 28, N100-N104 (2000)
8. Baeuerle PA and Baltimore D: NF-κB: Ten years after. Cell 87, 13-20 (1996)
9. Blackwell TS, Blackwell TR and Holden EP: In vivo antioxidant treatment suppresses nuclear factor-κB activation and neutrophilic lung inflammation. J Immunol 157: 1630-1637 (1996)
10. Liu SF, Ye X and Malik AB: In vivo inhibition of nuclear factor-κB activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. J Immunol 159, 3976-3983 (1997)
11. Hickenbottom SL, Grotta JC, Strong R, Denner LA and Aronowski J: Nuclear factor-κB and cell death after experimental intracerebral hemorrhage in rats. Stroke 30, 2472-2478 (1999)
12. Darber A. Analytical methods. In: Practical Protein Chemistry, A Hand Book. New York: John Wiley and Sons, 1986: 227-335.
13. Abraham E, Carmody A, Shenkar R and Arcaroli J: Neutrophils as early immunologic effectors in hemorrhage or endotoxemia-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 279, L1137-L1145 (2000)
14. Lowry OH, Rosebrogh NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193, 265-275 (1951)
15. Lee CH, Guo YL, Tsai PJ, Chang HY, Chen CR, Chen CW and Hsiue TR: Fatal acute pulmonary oedema ofter inhalation of fumes from polytetrafluoroethylene (PTFE). Eur Respir J 10,1408-1411 (1997)
16. Tsai PJ, Guo YL, Chen JL and Shieh HY: An integrated approach to initiate preventive strategies for workers exposed to Teflon pyrolytic gases in a plastic industry. J Occup Health 42, 297-303 (2000)
17. Blackwell TS and Christman JW: The role of nuclear factor-κB in cytokine gene regulation. Am J Respir Cell Mol Biol 17, 3-9 (1997)
18. John J: Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cellular Signalling 14, 879-897 (2002)
19. Shenkar R and Abraham E: Mechanisms of lung neutrophil activation after hemorrhage or endotoxemia, role of reactive oxygen intermediates, NF-κB, and cyclic AMP response element binding protein. J Immunol 163, 954-962 (1999)
20. Strieter RM, Kunkel SL, Keane MP and Standiford TJ: Chemokines in lung injury: Thomas A. Neff lecture. Chest 116 (Suppl 1), 103S-110S (1999)
21. Shames BD, Zallen GS, McIntyre RC, Bensard DD, Pulido EJ, Miller SA, Pomerantz BJ, Selzman CH, Meng X and Harken AH: Chemokines as mediators of diseases related to surgical conditions. Shock 14, 1-7 (2000)
22. Bach SP, Chinery R, O'Dwyer ST, Potten CS, Coffey RJ and Watson AJ: Pyrrolidinedithiocarbamate increases the therapeutic index of 5-fluorouracil in a mouse model. Gastroenterol 118, 81-89 (2000)